CHICAGO – At the American Society of Clinical Oncology's annual meeting this week, the US Food and Drug Administration highlighted the ways in which it is using real-world patient data to learn more about the safety and efficacy of precision oncology drugs and the extent to which diagnostics are used to guide treatment strategy.
At ASCO, FDA Discusses Use of Real-World Data Drawn From Flatiron Health's Clinico-Genomics Database
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.